GlassScriptPhysician profile
Abdul R Miah
NPI 1467848010
$1,089.23
in general payments reported to CMS, 2019-2025
19 companies · $599 in 2025
The $599 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.00 · 2023: $312 · 2024: $128 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.25 |
| Education | $157.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $134.87 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $120.79 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $116.67 | 2023 | Tagrisso |
| Alexion Pharmaceuticals, INC. | $93.60 | 2024-2025 | Soliris, Ultomiris |
| Incyte Corporation | $82.99 | 2023 | |
| Janssen Biotech, INC. | $81.06 | 2025 | Tecvayli, Erleada, Rybrevant |
| Daiichi Sankyo INC. | $79.72 | 2025 | Datroway, Injectafer, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $62.28 | 2025 | Fruzaqla, Iclusig |
| Janssen Scientific Affairs, LLC | $52.92 | 2024 | Carvykti, Talvey, Tecvayli |
| Beigene USA, INC. | $50.00 | 2022 | |
| Lilly USA, LLC | $40.69 | 2025 | Verzenio, Jaypirca |
| Beone Medicines USA, INC. | $29.05 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $26.05 | 2025 | Besremi |
| Pfizer INC. | $24.24 | 2025 | |
| Merck Sharp & Dohme LLC | $20.59 | 2025 | Keytruda, Welireg |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20.20 | 2025 | Ojjaara |
| Emd Serono, INC. | $19.10 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.19 | 2025 | |
| Adc Therapeutics America, INC. | $16.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Miah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.